Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Highlights

Highlights of This Issue

DOI:  Published September 2011
  • Article
  • Info & Metrics
  • PDF
Loading

Dual Inhibition of Insulin-like Growth Factor Receptor and mTOR Pathways

Naing et al., Page 6052

This phase I multicenter study enrolled 42 patients with advanced cancer who were treated with a combination of the mTOR inhibitor temsirolimus with cixutumumab. The combination was well tolerated. Clinical benefits were observed in Ewing sarcoma and adrenocortical carcinoma. Pharmacodynamic data suggest that cixutumumab alone or combined with temsirolimus increased plasma insulin-like growth factor (IGF)-1 and IGF binding protein 3. Assessment via 2[18F]fluoro-2-deoxy-D-glucose positron emission tomography combined with x-ray computed tomography showed the odds of achieving stable disease decreased by 58% (P = 0.1213) with a 1-unit increase in absolute change of standard uptake value from baseline to day 3.

Immunotoxin and TRAIL Combo Kill Resistant Cells

Du et al., Page 5926

Pancreatic cancers are resistant to most chemotherapeutic agents, and novel treatments are needed. Du and colleagues assessed the activity of an antimesothelin immunotoxin on pancreatic cancer cells and found that these cells are resistant to immunotoxin due to low levels of the proapoptotic protein Bak. Combining TRAIL or an anti-TRAIL receptor 2 antibody with immunotoxin caused synergistic cell death and reduced tumor volume in a xenograft mouse model. These data demonstrate that cancer cells with low BAK are resistant to immunotoxin treatment, and that combining immunotoxin with TRAIL or a TRAIL agonist antibody is an effective way to overcome such resistance.

FasL-844CC Predicts Poor Prognosis in Non–Small Cell Lung Cancer

Sung et al., Page 5991

Fas ligand (FasL)-844T/C polymorphism has a demonstrated association with tumor progression via immune escape. To explore the role of FasL haplotype on the outcome of resected non–small cell lung cancer (NSCLC), Sung and colleagues followed the survival and relapse of 385 NSCLC patients and determined their FasL-844 genotype. The FasL-844CC genotype was highly prevalent in patients with advanced tumors, who are prone to disease relapse. Additionally, patients with the FasL-844CC genotype had worse overall survival and relapse-free survival than did those with the FasL-844TT+TC genotype. Therefore, FasL-844 polymorphism evaluated by PCR restriction fragment length polymorphism may potentially predict disease relapse and prognosis in resected NSCLC.

Serum C18-Ceramide as a Novel Biomarker for Response

Saddoughi et al., Page 6097

Gemcitabine and doxorubicin (GEM/DOX) induced tumor suppressor sphingolipid C18-ceramide generation and inhibited head and neck squamous cell carcinoma (HNSCC) tumor growth in preclinical studies. To evaluate the clinical efficacy and relevance of this strategy, Saddoughi and colleagues conducted a phase II trial in patients with recurrent HNSCC. In 17 patients, the median progression-free survival was 1.6 months [95% confidence interval (CI): 1.4, 4.2], with a median survival of 5.6 months (95% CI: 3.8, 18.2). C18-ceramide elevation was observed in the serum of patients with response and stable disease, compared with progressive disease, suggesting that GEM/DOX-induced C18-ceramide may be a novel serum biomarker for monitoring therapeutic response.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Clinical Cancer Research: 17 (18)
September 2011
Volume 17, Issue 18
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Highlights of This Issue
Clin Cancer Res September 15 2011 (17) (18) 5839;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Clin Cancer Res September 15 2011 (17) (18) 5839;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Dual Inhibition of Insulin-like Growth Factor Receptor and mTOR Pathways
    • Immunotoxin and TRAIL Combo Kill Resistant Cells
    • FasL-844CC Predicts Poor Prognosis in Non–Small Cell Lung Cancer
    • Serum C18-Ceramide as a Novel Biomarker for Response
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Highlights of This Issue
  • Highlights of This Issue
  • Highlights of This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement